{"title":"超声治疗2型糖尿病女性运动引起的肌肉酸痛和疲劳缓解：一项随机对照试验","authors":"Tahereh Bameri, Mohammadreza Rezaeipour, Javad Nakhzari Khodakheir","doi":"10.1177/20420188251362091","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Exercise-induced muscle soreness and fatigue are significant barriers to physical activity in middle-aged women with type 2 diabetes (T2D), exacerbated by impaired tissue healing and chronic inflammation.</p><p><strong>Objectives: </strong>To evaluate whether post-exercise therapeutic ultrasound (TUS) effectively reduces exercise-induced muscle soreness and fatigue while improving metabolic and inflammatory biomarkers in women with T2D.</p><p><strong>Design: </strong>Randomized controlled trial.</p><p><strong>Methods: </strong>Thirty sedentary women with T2D (aged 41-49 years, glycated hemoglobin (HbA1c) 6.5%-9.0%) were randomized to a TUS group (<i>n</i> = 15) or control (<i>n</i> = 15). Both groups completed an 8-week aerobic cycling program (3 sessions/week, 45 min/session, 60%-70% VO<sub>2</sub>max). The TUS group received post-exercise ultrasound (3 MHz, 1 W/cm<sup>2</sup>, 7 min/leg) using the Intellect Mobile 2 device. Primary outcomes were pain (Von Korff scale) and fatigue (Borg scale), while secondary outcomes included fasting blood sugar (FBS), HbA1c, inflammatory markers (tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6)), and creatine kinase (CK), assessed at baseline and post-intervention. Linear mixed-effects models adjusted for baseline pain differences.</p><p><strong>Results: </strong>The TUS group showed marked decreases in pain (-2.2, 95% CI: -2.8 to -1.6, <i>p</i> < 0.001) and fatigue (-1.8, 95% CI: -2.4 to -1.2, <i>p</i> = 0.004) compared to controls. Secondary outcomes substantially improved: HbA1c (-0.5%, <i>p</i> = 0.03), FBS (-19.8 mg/dL, <i>p</i> = 0.01), TNF-α (-24.9 pg/mL, <i>p</i> < 0.001), IL-6 (-11.9 pg/mL, <i>p</i> < 0.001), and CK (-30 U/L, <i>p</i> = 0.01). No adverse events were reported.</p><p><strong>Conclusion: </strong>TUS is a safe, effective adjunct for reducing exercise-induced muscle soreness and fatigue in women with T2D, with benefits in glycemic control and inflammation. Larger trials with sham controls are needed.</p><p><strong>Trial registration: </strong>This trial was registered at the Iranian Registry of Clinical Trials (IRCT20211201053244N1) on June 21, 2022.</p>","PeriodicalId":22998,"journal":{"name":"Therapeutic Advances in Endocrinology and Metabolism","volume":"16 ","pages":"20420188251362091"},"PeriodicalIF":4.6000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397603/pdf/","citationCount":"0","resultStr":"{\"title\":\"Ultrasound therapy for exercise-induced muscle soreness and fatigue relief in women with type 2 diabetes: a randomized controlled trial.\",\"authors\":\"Tahereh Bameri, Mohammadreza Rezaeipour, Javad Nakhzari Khodakheir\",\"doi\":\"10.1177/20420188251362091\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Exercise-induced muscle soreness and fatigue are significant barriers to physical activity in middle-aged women with type 2 diabetes (T2D), exacerbated by impaired tissue healing and chronic inflammation.</p><p><strong>Objectives: </strong>To evaluate whether post-exercise therapeutic ultrasound (TUS) effectively reduces exercise-induced muscle soreness and fatigue while improving metabolic and inflammatory biomarkers in women with T2D.</p><p><strong>Design: </strong>Randomized controlled trial.</p><p><strong>Methods: </strong>Thirty sedentary women with T2D (aged 41-49 years, glycated hemoglobin (HbA1c) 6.5%-9.0%) were randomized to a TUS group (<i>n</i> = 15) or control (<i>n</i> = 15). Both groups completed an 8-week aerobic cycling program (3 sessions/week, 45 min/session, 60%-70% VO<sub>2</sub>max). The TUS group received post-exercise ultrasound (3 MHz, 1 W/cm<sup>2</sup>, 7 min/leg) using the Intellect Mobile 2 device. Primary outcomes were pain (Von Korff scale) and fatigue (Borg scale), while secondary outcomes included fasting blood sugar (FBS), HbA1c, inflammatory markers (tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6)), and creatine kinase (CK), assessed at baseline and post-intervention. Linear mixed-effects models adjusted for baseline pain differences.</p><p><strong>Results: </strong>The TUS group showed marked decreases in pain (-2.2, 95% CI: -2.8 to -1.6, <i>p</i> < 0.001) and fatigue (-1.8, 95% CI: -2.4 to -1.2, <i>p</i> = 0.004) compared to controls. Secondary outcomes substantially improved: HbA1c (-0.5%, <i>p</i> = 0.03), FBS (-19.8 mg/dL, <i>p</i> = 0.01), TNF-α (-24.9 pg/mL, <i>p</i> < 0.001), IL-6 (-11.9 pg/mL, <i>p</i> < 0.001), and CK (-30 U/L, <i>p</i> = 0.01). No adverse events were reported.</p><p><strong>Conclusion: </strong>TUS is a safe, effective adjunct for reducing exercise-induced muscle soreness and fatigue in women with T2D, with benefits in glycemic control and inflammation. Larger trials with sham controls are needed.</p><p><strong>Trial registration: </strong>This trial was registered at the Iranian Registry of Clinical Trials (IRCT20211201053244N1) on June 21, 2022.</p>\",\"PeriodicalId\":22998,\"journal\":{\"name\":\"Therapeutic Advances in Endocrinology and Metabolism\",\"volume\":\"16 \",\"pages\":\"20420188251362091\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397603/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Endocrinology and Metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/20420188251362091\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Endocrinology and Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20420188251362091","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
背景：运动引起的肌肉酸痛和疲劳是2型糖尿病（T2D）中年女性体育活动的重要障碍，组织愈合受损和慢性炎症加剧了这种障碍。目的：评估运动后治疗性超声（TUS）是否能有效减轻运动引起的肌肉酸痛和疲劳，同时改善女性T2D的代谢和炎症生物标志物。设计：随机对照试验。方法：30名患有T2D的久坐女性（年龄41-49岁，糖化血红蛋白（HbA1c） 6.5%-9.0%）随机分为TUS组（n = 15）和对照组（n = 15）。两组都完成了为期8周的有氧自行车运动（3次/周，45分钟/次，最大摄氧量60%-70%）。TUS组接受运动后超声（3 MHz, 1 W/cm2, 7 min/腿），使用Intellect Mobile 2设备。主要结局是疼痛（Von Korff量表）和疲劳（Borg量表），次要结局包括空腹血糖（FBS）、糖化血红蛋白（HbA1c）、炎症标志物(肿瘤坏死因子-α （TNF-α)和白细胞介素-6 (IL-6)）和肌酸激酶（CK），在基线和干预后评估。根据基线疼痛差异调整的线性混合效应模型。结果：与对照组相比，TUS组疼痛明显减轻（-2.2,95% CI: -2.8 ~ -1.6, p p = 0.004）。次要结果大大改善:糖化血红蛋白(-0.5%,p = 0.03),的边后卫(-19.8 mg / dL, p = 0.01),肿瘤坏死因子-α(-24.9 pg / mL, p p p = 0.01)。无不良事件报告。结论：TUS是一种安全、有效的辅助药物，可减轻T2D女性运动引起的肌肉酸痛和疲劳，对血糖控制和炎症有好处。需要更大规模的假对照试验。试验注册：该试验于2022年6月21日在伊朗临床试验注册中心（IRCT20211201053244N1）注册。
Ultrasound therapy for exercise-induced muscle soreness and fatigue relief in women with type 2 diabetes: a randomized controlled trial.
Background: Exercise-induced muscle soreness and fatigue are significant barriers to physical activity in middle-aged women with type 2 diabetes (T2D), exacerbated by impaired tissue healing and chronic inflammation.
Objectives: To evaluate whether post-exercise therapeutic ultrasound (TUS) effectively reduces exercise-induced muscle soreness and fatigue while improving metabolic and inflammatory biomarkers in women with T2D.
Design: Randomized controlled trial.
Methods: Thirty sedentary women with T2D (aged 41-49 years, glycated hemoglobin (HbA1c) 6.5%-9.0%) were randomized to a TUS group (n = 15) or control (n = 15). Both groups completed an 8-week aerobic cycling program (3 sessions/week, 45 min/session, 60%-70% VO2max). The TUS group received post-exercise ultrasound (3 MHz, 1 W/cm2, 7 min/leg) using the Intellect Mobile 2 device. Primary outcomes were pain (Von Korff scale) and fatigue (Borg scale), while secondary outcomes included fasting blood sugar (FBS), HbA1c, inflammatory markers (tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6)), and creatine kinase (CK), assessed at baseline and post-intervention. Linear mixed-effects models adjusted for baseline pain differences.
Results: The TUS group showed marked decreases in pain (-2.2, 95% CI: -2.8 to -1.6, p < 0.001) and fatigue (-1.8, 95% CI: -2.4 to -1.2, p = 0.004) compared to controls. Secondary outcomes substantially improved: HbA1c (-0.5%, p = 0.03), FBS (-19.8 mg/dL, p = 0.01), TNF-α (-24.9 pg/mL, p < 0.001), IL-6 (-11.9 pg/mL, p < 0.001), and CK (-30 U/L, p = 0.01). No adverse events were reported.
Conclusion: TUS is a safe, effective adjunct for reducing exercise-induced muscle soreness and fatigue in women with T2D, with benefits in glycemic control and inflammation. Larger trials with sham controls are needed.
Trial registration: This trial was registered at the Iranian Registry of Clinical Trials (IRCT20211201053244N1) on June 21, 2022.
期刊介绍：
Therapeutic Advances in Endocrinology and Metabolism delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of endocrinology and metabolism.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
